Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of “Hold” by Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have received a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $56.40.

PSTV has been the subject of a number of recent analyst reports. D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Ascendiant Capital Markets lowered their price objective on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Tuesday, April 21st.

Institutional Investors Weigh In On Plus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. L1 Global Manager Pty Ltd bought a new stake in shares of Plus Therapeutics in the 4th quarter worth approximately $1,167,000. Jane Street Group LLC purchased a new stake in Plus Therapeutics in the fourth quarter worth $525,000. Geode Capital Management LLC lifted its stake in Plus Therapeutics by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after acquiring an additional 589,544 shares during the period. Virtu Financial LLC purchased a new stake in Plus Therapeutics in the fourth quarter worth $254,000. Finally, XTX Topco Ltd bought a new stake in Plus Therapeutics in the fourth quarter valued at $127,000. Hedge funds and other institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Stock Performance

Shares of PSTV stock opened at $3.82 on Thursday. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42. The stock has a 50 day moving average price of $5.28 and a two-hundred day moving average price of $6.89. The company has a market capitalization of $26.28 million, a P/E ratio of -1.66 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Friday, May 15th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.97 million. As a group, equities analysts predict that Plus Therapeutics will post -3.76 earnings per share for the current year.

About Plus Therapeutics

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.